News

Yahoo Finance1mon
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers - Yahoo Finance
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®YAVNE, Israel, May 13, 2025 (GLOBE ...
Business Insider8y
Collagenase SANTYL® Ointment advances pressure ulcers through the healing process faster, new study suggests - Markets Insider
LONDON, May 4, 2017 /PRNewswire/ -- Smith & Nephew (LSE:SN, NYSE:SNN), the global medical technology business, welcomes the publication of a new research paper showing how pressure ulcers, when ...
Yahoo Finance1y
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study - Yahoo Finance
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in ...
Stockhouse1y
2024-02-12 | MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study - Stockhouse
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound ...
Nasdaq1mon
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers | Nasdaq
Compared to SANTYL, ... The article, titled “Bromelain-Based Debridement Versus Collagenase Ointment Debridement of Venous Leg Ulcers: Post Hoc Analysis of the ChronEx Trial, ...
KTLA1y
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study - KTLA
YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of head-to ...
Yahoo Finance1mon
MediWound Announces Publication of Phase II EscharEx® Data Demonstrating Superiority Over Collagenase in Venous Leg Ulcers - Yahoo Finance
Post hoc analysis published in the peer-reviewed journal Wounds highlights EscharEx®’s superior clinical performance and comparable safety profile to SANTYL®YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE ...
WREG1y
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of head-to ...
NBC4 Columbus1y
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study - NBC4 WCMH-TV
YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of head-to ...
WDAF-TV1y
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study - FOX 4 Kansas City WDAF-TV
YAVNE, Israel, Feb. 12, 2024 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), the global leader in next-generation enzymatic therapeutics for tissue repair today announced the results of head-to ...
Yahoo Finance1y
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study - Yahoo Finance
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients ...